NCT06241742View on ClinicalTrials.gov

Evaluating Ability of HT-6184 to Reduce Inflammation and Pain After Third Molar Extraction

PHASE2CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

February 12, 2024

Primary Completion Date

April 30, 2024

Study Completion Date

April 30, 2024

Conditions
Pain
Interventions
DRUG

HT-6184

Single, oral dose of HT-6184

DRUG

HT-6184 Placebo

Single, oral dose of placebo

Trial Locations (1)

84107

CenExel JBR, Murray

Sponsors
All Listed Sponsors
lead

Halia Therapeutics, Inc.

INDUSTRY